Comparing Nemaura Medical (NASDAQ:NMRD) and Inspire Medical Systems (NYSE:INSP)

Nemaura Medical (NASDAQ:NMRD) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Nemaura Medical and Inspire Medical Systems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
Inspire Medical Systems	0	3	8	0	2.73

Inspire Medical Systems has a consensus target price of $228.82, indicating a potential upside of 22.68%. Given Inspire Medical Systems’ stronger consensus rating and higher possible upside, analysts plainly believe Inspire Medical Systems is more favorable than Nemaura Medical.

Earnings & Valuation

This table compares Nemaura Medical and Inspire Medical Systems”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$80,000.00	0.00	-$14.14 million	($0.39)	N/A
Inspire Medical Systems	$802.80 million	6.89	$53.51 million	$1.73	107.81

Inspire Medical Systems has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nemaura Medical and Inspire Medical Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
Inspire Medical Systems	6.67%	8.19%	7.09%

Institutional & Insider Ownership

4.4% of Nemaura Medical shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 40.4% of Nemaura Medical shares are held by company insiders. Comparatively, 4.1% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Nemaura Medical has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Summary

Inspire Medical Systems beats Nemaura Medical on 11 of the 12 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About Inspire Medical Systems

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.